AKT1 and Alzheimer disease: Some selective Erβ receptor agonists, such as gypenoside XVII and genistein, can improve the clinical symptoms of AD through ER-dependent activation of the PI3K/Akt pathway, inducing diminished oxidative stress and decreasing tau phosphorylation (Bagheri et al., 2011; Meng et al., 2014).